Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

1. Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.Annals of hematology · 2024
   Pooled it
2. Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant.Annals of hematology · 2026
   Trial
3. Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).Annals of hematology · 2025
   Trial
4. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.Bone marrow transplantation · 2016
   Trial
5. Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results.PloS one · 2026
   Article
6. The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs.Frontiers in oncology · 2025
   Review
7. Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone.Cancer medicine · 2024
   Article
8. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
   Article
9. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments.Annals of hematology · 2023
   Review
10. Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices.PloS one · 2023
    Article
11. Initial Therapeutic Approaches to Patients with Multiple Myeloma.Advances in therapy · 2021
    Review
12. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.International journal of hematology · 2019
    Article
13. Current status of autologous stem cell transplantation for multiple myeloma.Blood cancer journal · 2019
    Review
14. Impact of lenalidomide exposure on blood cell collection for autotransplants in persons with POEMS syndrome.Archives of medical science : AMS · 2018
    Article
15. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.The Journal of clinical investigation · 2016
    Article
16. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Paediatric drugs · 2014
    Review
17. The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).Technology in cancer research & treatment
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as